Advanced search
Publication Cover
Postgraduate Medicine Volume 132, 2020 - Issue 8
Submit an article Journal homepage
133
Views
3
CrossRef citations to date
0
Altmetric
Clinical focus: Cardiometabolic Conditions - Original Research

Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes

Luiz Paulo José MarquesRenal Unit of Gaffrée and Guinle University Hospital - Department of Medicine, Federal University of Rio de Janeiro State, Rio de Janeiro, BrazilCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2235-7257View further author information
ORCID Icon,
Nayanne Aguiar MendonçaRenal Unit of Gaffrée and Guinle University Hospital - Department of Medicine, Federal University of Rio de Janeiro State, Rio de Janeiro, BrazilORCID Iconhttps://orcid.org/0000-0002-4016-7775View further author information
ORCID Icon,
Lucas MüllerRenal Unit of Gaffrée and Guinle University Hospital - Department of Medicine, Federal University of Rio de Janeiro State, Rio de Janeiro, BrazilORCID Iconhttps://orcid.org/0000-0003-1933-8995View further author information
ORCID Icon,
Ana Carolina Pereira Diaz AndréRenal Unit of Gaffrée and Guinle University Hospital - Department of Medicine, Federal University of Rio de Janeiro State, Rio de Janeiro, BrazilORCID Iconhttps://orcid.org/0000-0002-6954-7704View further author information
ORCID Icon,
Eugênio Pacelle Queiroz MadeiraRenal Unit of Gaffrée and Guinle University Hospital - Department of Medicine, Federal University of Rio de Janeiro State, Rio de Janeiro, BrazilORCID Iconhttps://orcid.org/0000-0003-4328-2469View further author information
ORCID Icon &
Lygia Maria Soares Fernandes VieiraRenal Unit of Gaffrée and Guinle University Hospital - Department of Medicine, Federal University of Rio de Janeiro State, Rio de Janeiro, BrazilORCID Iconhttps://orcid.org/0000-0003-4167-3642View further author information
ORCID Icon
Pages 697-701 | Received 15 Jun 2020, Accepted 26 Aug 2020, Published online: 05 Oct 2020

References

  • Cho JD, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
  • Marques LPJ, Flores JT, Barros Junior OO, et al. Epidemiological and clinical aspects of urinary tract infection in community-dwelling elderly women. Braz J Infect Dis. 2012;16:436–441.
  • Boyko EJ, Fihn SD, Scholes D, et al. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161:557–564.
  • Wilke T, Böttger B, Berg B, et al. Healthcare burden and costs associated with urinary tract infections in type2 diabetes mellitus patients: an analysis based on a large sample of 456,586 German patients. Nephron. 2016;132:215–226.
  • Nitzan O, Elias M, Chazan B, et al. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diab Metab Synd Obes. 2015;8:129–136.
  • Pandey J, Tamrakar AK. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018). Expert Opin Ther Pat. 2019;29:369–384.
  • Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18:295–311.
  • Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61:2118–2125.
  • Soh PN, Vidal F, Huyghe E, et al. Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab. 2016;42:16–24.
  • Alvisi S, Gava G, Orsili I, et al. Vaginal health in menopausal women. Medicina (B Aires). 2019;55(10):615. .
  • Lega IC, Bronskill SE, Michael A, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019;21:2394–2404.
  • Rodrigues CF, Rodrigues ME, Henriques M. Candida sp. Infections in patients with diabetes mellitus. J Clin Med. 2019;76:1–41.
  • Yokoyama H, Nagao A, Watanabe S, et al. Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real-world practice for women with type 2 diabetes. J Diabetes Investig. 2019;10::439–4450.
  • US Food and Drug Administration, drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Silver Spring (MD): US Food and Drug Administration; 2015. Available from: www.fda.gov/Drugs/DrugSafety/ucm475463.htm
  • Li D, Wang T, Shen S, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348–355.
  • Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783–794.
  • Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274.
  • Shen J, Yang J, Zhao BA. Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use. Diabetes Ther. 2019;10:1043–1050.
  • Puckrin R, Saltiel MP, Reynier P, et al. SGTL-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55:503–514.
  • Dave CV, Schneeweiss S, Kim D, et al. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study. Ann Intern Med. 2019;171:248–256.
  • Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Posgraduate Med. 2016;128:409–417.
  • Turan H, Serefhanoglu K, Torun AN, et al. Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus. Jpn J Infect Dis. 2008;61:236–238.
  • Renko M, Tapanainen P, Tossvainen P, et al. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34:230–235.
  • Nicolle LE. The paradigm shift to non-treatment of asymptomatic bacteriuria. Pathogens. 2016;5:38.
  • Cameron AP, Campeau L, Brucker BM, et al. Best practice policy statement on urodynamic antibiotic prophylaxis in the non-index patient. Neurourol Urodyn. 2017;9999:1–12.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.